141 related articles for article (PubMed ID: 36914591)
1. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.
Mulatero P; Groessl M; Vogt B; Schumacher C; Steele RE; Brooks A; Hossack S; Brunner HR
Br J Clin Pharmacol; 2023 Aug; 89(8):2483-2496. PubMed ID: 36914591
[TBL] [Abstract][Full Text] [Related]
2. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial.
Mulatero P; Wuerzner G; Groessl M; Sconfienza E; Damianaki A; Forestiero V; Vogt B; Brunner H; Gerlock T; Steele R; Schumacher C
EClinicalMedicine; 2024 May; 71():102576. PubMed ID: 38618204
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone synthase inhibition in humans.
Azizi M; Amar L; Menard J
Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
[TBL] [Abstract][Full Text] [Related]
5. Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate.
Pignatti E; Kollar J; Hafele E; Schuster D; Steele RE; Vogt B; Schumacher C; Groessl M
J Steroid Biochem Mol Biol; 2023 Dec; 235():106409. PubMed ID: 37827219
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
[TBL] [Abstract][Full Text] [Related]
7. Stress-induced Aldosterone Hyper-Secretion in a Substantial Subset of Patients With Essential Hypertension.
Markou A; Sertedaki A; Kaltsas G; Androulakis II; Marakaki C; Pappa T; Gouli A; Papanastasiou L; Fountoulakis S; Zacharoulis A; Karavidas A; Ragkou D; Charmandari E; Chrousos GP; Piaditis GP
J Clin Endocrinol Metab; 2015 Aug; 100(8):2857-64. PubMed ID: 25974737
[TBL] [Abstract][Full Text] [Related]
8. LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.
Sloan-Lancaster J; Raddad E; Flynt A; Jin Y; Voelker J; Miller JW
J Renin Angiotensin Aldosterone Syst; 2017; 18(3):1470320317717883. PubMed ID: 28814143
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
[TBL] [Abstract][Full Text] [Related]
10. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio.
Lim PO; Macdonald TM; Holloway C; Friel E; Anderson NH; Dow E; Jung RT; Davies E; Fraser R; Connell JM
J Clin Endocrinol Metab; 2002 Sep; 87(9):4398-402. PubMed ID: 12213905
[TBL] [Abstract][Full Text] [Related]
11. Expression of aldosterone synthase and adrenocorticotropic hormone receptor in adrenal incidentalomas from normotensive and hypertensive patients: Distinguishing subclinical or atypical primary aldosteronism from adrenal incidentaloma.
Cao CX; Yang XC; Gao YX; Zhuang M; Wang KP; Sun LJ; Wang XS
Int J Mol Med; 2012 Dec; 30(6):1396-402. PubMed ID: 23023242
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.
Amar L; Azizi M; Menard J; Peyrard S; Watson C; Plouin PF
Hypertension; 2010 Nov; 56(5):831-8. PubMed ID: 20837883
[TBL] [Abstract][Full Text] [Related]
13. Age-Related Autonomous Aldosteronism.
Nanba K; Vaidya A; Williams GH; Zheng I; Else T; Rainey WE
Circulation; 2017 Jul; 136(4):347-355. PubMed ID: 28566337
[TBL] [Abstract][Full Text] [Related]
14. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study.
Andersen K; Hartman D; Peppard T; Hermann D; Van Ess P; Lefkowitz M; Trapani A
J Clin Hypertens (Greenwich); 2012 Sep; 14(9):580-7. PubMed ID: 22947355
[TBL] [Abstract][Full Text] [Related]
15. Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism.
Balaş M; Zosin I; Maser-Gluth C; Hermsen D; Cupisti K; Schott M; Schinner S; Knoefel WT; Scherbaum WA; Willenberg HS
Hypertens Res; 2010 Aug; 33(8):850-6. PubMed ID: 20520614
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
[TBL] [Abstract][Full Text] [Related]
17. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.
Stowasser M; Bachmann AW; Huggard PR; Rossetti TR; Gordon RD
J Clin Endocrinol Metab; 2000 Jun; 85(6):2160-6. PubMed ID: 10852446
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
19. A Chinese pedigree with glucocorticoid remediable aldosteronism.
Liu X; Jin L; Zhang H; Ma W; Song L; Zhou X; Cai J
Hypertens Res; 2021 Nov; 44(11):1428-1433. PubMed ID: 34462604
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study.
Freel EM; Ingram M; Friel EC; Fraser R; Brown M; Samani NJ; Caulfield M; Munroe P; Farrall M; Webster J; Clayton D; Dominiczak AF; Davies E; Connell JM
Clin Endocrinol (Oxf); 2007 Dec; 67(6):832-8. PubMed ID: 17651452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
